268 related articles for article (PubMed ID: 32196303)
1. Prediction of the Binding Affinities and Selectivity for CB1 and CB2 Ligands Using Homology Modeling, Molecular Docking, Molecular Dynamics Simulations, and MM-PBSA Binding Free Energy Calculations.
Ji B; Liu S; He X; Man VH; Xie XQ; Wang J
ACS Chem Neurosci; 2020 Apr; 11(8):1139-1158. PubMed ID: 32196303
[TBL] [Abstract][Full Text] [Related]
2. Virtual screening using docking and molecular dynamics of cannabinoid analogs against CB
Aviz-Amador A; Contreras-Puentes N; Mercado-Camargo J
Comput Biol Chem; 2021 Dec; 95():107590. PubMed ID: 34700256
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.
Ashton JC; Wright JL; McPartland JM; Tyndall JD
Curr Med Chem; 2008; 15(14):1428-43. PubMed ID: 18537620
[TBL] [Abstract][Full Text] [Related]
4. Exploring the Ligand Efficacy of Cannabinoid Receptor 1 (CB1) using Molecular Dynamics Simulations.
Jung SW; Cho AE; Yu W
Sci Rep; 2018 Sep; 8(1):13787. PubMed ID: 30213978
[TBL] [Abstract][Full Text] [Related]
5. Binding Modes and Selectivity of Cannabinoid 1 (CB1) and Cannabinoid 2 (CB2) Receptor Ligands.
Yang JF; Williams AH; Penthala NR; Prather PL; Crooks PA; Zhan CG
ACS Chem Neurosci; 2020 Oct; 11(20):3455-3463. PubMed ID: 32997485
[TBL] [Abstract][Full Text] [Related]
6. Crystal Structure of the Human Cannabinoid Receptor CB2.
Li X; Hua T; Vemuri K; Ho JH; Wu Y; Wu L; Popov P; Benchama O; Zvonok N; Locke K; Qu L; Han GW; Iyer MR; Cinar R; Coffey NJ; Wang J; Wu M; Katritch V; Zhao S; Kunos G; Bohn LM; Makriyannis A; Stevens RC; Liu ZJ
Cell; 2019 Jan; 176(3):459-467.e13. PubMed ID: 30639103
[TBL] [Abstract][Full Text] [Related]
7. The agonist binding mechanism of human CB2 receptor studied by molecular dynamics simulation, free energy calculation and 3D-QSAR studies.
Chen JJ; Han S; Cao Y; Chen JZ
Yao Xue Xue Bao; 2013 Sep; 48(9):1436-49. PubMed ID: 24358778
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
[TBL] [Abstract][Full Text] [Related]
9. Modeling of ligand binding to G protein coupled receptors: cannabinoid CB1, CB2 and adrenergic β 2 AR.
Latek D; Kolinski M; Ghoshdastider U; Debinski A; Bombolewski R; Plazinska A; Jozwiak K; Filipek S
J Mol Model; 2011 Sep; 17(9):2353-66. PubMed ID: 21365223
[TBL] [Abstract][Full Text] [Related]
10. 7-Azaindolequinuclidinones (7-AIQD): A novel class of cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor ligands.
Penthala NR; Shoeib A; Dachavaram SS; Cabanlong CV; Yang J; Zhan CG; Prather PL; Crooks PA
Bioorg Med Chem Lett; 2020 Nov; 30(22):127501. PubMed ID: 32882418
[TBL] [Abstract][Full Text] [Related]
11. Comparative molecular dynamics simulations of the potent synthetic classical cannabinoid ligand AMG3 in solution and at binding site of the CB1 and CB2 receptors.
Durdagi S; Reis H; Papadopoulos MG; Mavromoustakos T
Bioorg Med Chem; 2008 Aug; 16(15):7377-87. PubMed ID: 18595717
[TBL] [Abstract][Full Text] [Related]
12. Computational investigation on the binding modes of Rimonabant analogs with CB1 and CB2.
Liu C; Yuan C; Wu P; Zhu C; Fang H; Wang L; Fu W
Chem Biol Drug Des; 2018 Sep; 92(3):1699-1707. PubMed ID: 29797785
[TBL] [Abstract][Full Text] [Related]
13. Structure-Based Virtual Screening and Molecular Dynamics Simulation Assessments of Depsidones as Possible Selective Cannabinoid Receptor Type 2 Agonists.
Mohamed GA; Omar AM; AlKharboush DF; Fallatah MA; Sindi IA; El-Agamy DS; Ibrahim SRM
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838749
[TBL] [Abstract][Full Text] [Related]
14. Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-G
Hua T; Li X; Wu L; Iliopoulos-Tsoutsouvas C; Wang Y; Wu M; Shen L; Brust CA; Nikas SP; Song F; Song X; Yuan S; Sun Q; Wu Y; Jiang S; Grim TW; Benchama O; Stahl EL; Zvonok N; Zhao S; Bohn LM; Makriyannis A; Liu ZJ
Cell; 2020 Feb; 180(4):655-665.e18. PubMed ID: 32004463
[TBL] [Abstract][Full Text] [Related]
15. Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist.
Pandey P; Roy KK; Doerksen RJ
J Biomol Struct Dyn; 2020 Jan; 38(1):32-47. PubMed ID: 30652534
[TBL] [Abstract][Full Text] [Related]
16. Highly Selective, Amine-Derived Cannabinoid Receptor 2 Probes.
Westphal MV; Sarott RC; Zirwes EA; Osterwald A; Guba W; Ullmer C; Grether U; Carreira EM
Chemistry; 2020 Jan; 26(6):1380-1387. PubMed ID: 31961047
[TBL] [Abstract][Full Text] [Related]
17. Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study.
Montero C; Campillo NE; Goya P; Páez JA
Eur J Med Chem; 2005 Jan; 40(1):75-83. PubMed ID: 15642412
[TBL] [Abstract][Full Text] [Related]
18. Tricyclic Pyrazole-Based Compounds as Useful Scaffolds for Cannabinoid CB
Asproni B; Murineddu G; Corona P; Pinna GA
Molecules; 2021 Apr; 26(8):. PubMed ID: 33917187
[TBL] [Abstract][Full Text] [Related]
19. Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors.
Tham M; Yilmaz O; Alaverdashvili M; Kelly MEM; Denovan-Wright EM; Laprairie RB
Br J Pharmacol; 2019 May; 176(10):1455-1469. PubMed ID: 29981240
[TBL] [Abstract][Full Text] [Related]
20. CB1 and CB2 cannabinoid receptor binding studies based on modeling and mutagenesis approaches.
Ortega-Gutiérrez S; López-Rodríguez ML
Mini Rev Med Chem; 2005 Jul; 5(7):651-8. PubMed ID: 16026311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]